Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 4, 2007BloodOpen Access

Response to B-cell–depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura

View Full Paper
Ask AI
Bookmark
Share

Authors

RSRoberto StasiUniversity of SalentoGPGiovanni Del PoetaUniversity of Rome Tor VergataESElisa StipaSt. Eugenio Hospital

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Stasi et al. (2007) studied this question.

synapsesocial.com/papers/6a956297948c2c98a4f5900ahttps://doi.org/10.1182/blood-2007-02-068999
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effects of Interferon-α Therapy on Immune Parameters in Immune Thrombocytopenic Purpura1996 · 29 citations
  2. 2Phenotypic and clonal analysis of T lymphocytes in childhood immune thrombocytopenic purpura1993 · 91 citations
  3. 3Long Term Follow-Up of Patients with Immune Thrombocytopenic Purpura (ITP) Whose Initial Response to Rituximab Lasted a Minimum of 1 Year.2006 · 25 citations